

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY EVALUATION PROGRAMME**

**Equality impact assessment – Scoping**

**HST Cerliponase alfa for treating neuronal ceroid  
lipofuscinosis type 2 (review of HST12) [ID6145]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, it was highlighted that patients from ethnic minority backgrounds may access healthcare less well and may be diagnosed later and may therefore be at risk of not qualifying for treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee will need to make this judgement in the light of the full available evidence and consider whether any recommendations it makes will disadvantage any people from a protected group.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 31 October 2023